501701-43-5

Basic information

• Product Name: 4-(Chlorocarbonyl)-2,6-difluoroanisole
• Synonyms: 3,5-Difluoro-4-methoxybenzoyl chloride 99%;4-(Chlorocarbonyl)-2,6-difluoroanisole;4-(Chlorocarbonyl)-2,6-difluoroanisole, 4-(Chloroformyl)-2,6-difluoroanisole;3,5-Difluoro-4-methoxybenzoylchloride99%
• CAS NO: 501701-43-5
• Molecular Formula: C₈H₅ClF₂O₂
• Molecular Weight: 206.5739064
• Mol File: 501701-43-5.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(Chlorocarbonyl)-2,6-difluoroanisole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Chlorocarbonyl)-2,6-difluoroanisole(501701-43-5)
• EPA Substance Registry System: 4-(Chlorocarbonyl)-2,6-difluoroanisole(501701-43-5)

Safety Data

• Hazardous Substances Data: 501701-43-5(Hazardous Substances Data)

Upstream product

• 319-60-8 3,5-difluoro-4-methoxybenzoic acid 
• 79-37-8 oxalyl dichloride 

Downstream Products

• 1126079-25-1 N-(3,5-dibromo-4-hydroxyphenyl)-3,5-difluoro-4-methoxybenzamide 
• 1094325-48-0 N-(1,2-dimethylpropyl)-3,5-difluoro-4-methoxybenzamide 
• 1198153-41-1 (3,5-difluoro-4-methoxy-phenyl)-(2,3-dihydro-pyrido[4,3-b][1,4]oxazin-4-yl)-methanone 
• 1285572-87-3 3-(3,5-difluoro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 
• 1285575-02-1 3-(3,5-difluoro-4-methoxybenzoyl)-2,3-dihydro-1,1-dioxo-1,3-benzothiazole 
• 1285575-01-0 3-(3,5-difluoro-4-methoxybenzoyl)-2,3-dihydro-1,3-benzothiazole 

Relevant articles and documents

Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery

Using structure-guided design, several cell based assays, and microdosed positron emission tomography (PET) imaging, we identified a series of highly potent, selective, and brain-penetrant oxazole-4-carboxamide-based inhibitors of glycogen synthase kinase-3 (GSK-3). An isotopologue of our first-generation lead, [3H]PF-367, demonstrates selective and specific target engagement in vitro, irrespective of the activation state. We discovered substantial ubiquitous GSK-3-specific radioligand binding in Tg2576 Alzheimer's disease (AD), suggesting application for these compounds in AD diagnosis and identified [11C]OCM-44 as our lead GSK-3 radiotracer, with optimized brain uptake by PET imaging in nonhuman primates. GSK-3β-isozyme selectivity was assessed to reveal OCM-51, the most potent (IC50 = 0.030 nM) and selective (>10-fold GSK-3β/GSK-3α) GSK-3β inhibitor known to date. Inhibition of CRMP2T514 and tau phosphorylation, as well as favorable therapeutic window against WNT/β-catenin signaling activation, was observed in cells.

NOVEL PHENOL DERIVATIVE

Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in FIG. 1; a pharmaceutically acceptable salt t

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.